Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
185 Leser
Artikel bewerten:
(0)

Interventional Pulmonology Market is expected to exhibit a CAGR of more than 4% over the forecast period (2021 - 2031) - Persistence Market Research

NEW YORK, March 16, 2021 /PRNewswire/ -- Interventional pulmonology is an area of pulmonary medicine that deals specifically with minimally invasive endoscopic and percutaneous procedures for the diagnosis and treatment of neoplastic as well as non-neoplastic diseases of the airways, lungs, and pleura. Rise in the number of COPD cases across the world is expected to boost demand over the coming years. Need for faster recovery time and reduced pain during procedures and surgeries for respiratory disorders has strengthened the market. Leading manufacturers of interventional pulmonology devices are focusing on geographical expansion to increase revenue and add new repair and service centre in emerging countries through the acquisition of local players.

Persistence_Market_Research_Logo

Various awareness programs have been initiated by healthcare providers and health organizations/societies such as environmental programs, medication maintenance programs, and online education programs for public and healthcare professionals across the globe to control asthma, COPD, and other respiratory diseases. Major companies such as Boston Scientific Corporation, Olympus Corporation, and FUJIFILM Corporation, besides others, are focused on spreading awareness regarding respiratory diseases.

As per Persistence Market Research analysis, the global interventional pulmonology market is expected to exhibit a CAGR of more than 4% over the forecast period (2021 - 2031).

Key Takeaways from Study

  • IP diagnostic devices are expected to hold maximum revenue share under products.
  • Lung cancer is projected to be the dominant segment among indications, in terms of revenue. The segment accounted for 26.6% share in 2020.
  • The U.S., followed by Europe, is expected to hold substantial revenue share in the global interventional pulmonology market.
  • Emerging economies such as China, India, Brazil, Mexico, and South Africa have a large COPD patient pool, and rising disposable income of patients with increased healthcare expenditure would encourage interventional pulmonology device manufacturers to enter these markets.
  • The interventional pulmonology space faced adverse effects due to the COVID-19 crisis as a result of supply chain disruptions and economic impact of the pandemic on small- and medium-sized enterprises.
  • Hospitals and diagnostic centers to account for bulk of the market share (around ¾).

Request for sample report: https://www.persistencemarketresearch.com/samples/12544

"Rising global prevalence of various respiratory diseases has increased demand for effective diagnosis and treatment in order to better manage the progression rate of these diseases," says a Persistence Market Research analyst.

Ask an Expert for the methodology of report: https://www.persistencemarketresearch.com/ask-an-expert/12544

Acquisitions of Small & Medium Players - Imperative Strategy for Market Players

Given the consolidation in the market, bigger players are focusing on the acquisition of small and medium market players. This trend is being observed across North America and Europe. This is dominated by players with a strong regional distribution presence in terms of direct sales force and medical ventilator product manufacturing.

Get Full Access of Report: https://www.persistencemarketresearch.com/checkout/12544

What else is in the report?

Persistence Market Research offers actionable insights and unique perspective on the interventional pulmonology market in its latest study, presenting historical demand assessment of 2016 - 2019 and projections for 2021-2031, based on product (Electromagnetic Navigation Bronchoscopy (ENB), IP Diagnostic Devices, IP therapeutic devices), indication (Asthma, Lung Cancer, COPD, Foreign Body Extraction, Tracheal and Bronchial Stenosis), and end user (Hospitals, Pulmonology Clinics, Ambulatory Surgical Centers, Diagnostic Centers), across seven key regions of the world.

Browse Research Release at: https://www.persistencemarketresearch.com/market-reports.asp

Browse End-to-end Market: Healthcare

Related Reports:

  • Pulmonary Renal Syndrome Treatment Market: https://www.persistencemarketresearch.com/market-research/pulmonary-renal-syndrome-treatment-market.asp
  • Pulmonary Hemosiderosis Market:https://www.persistencemarketresearch.com/market-research/pulmonary-hemosiderosis-market.asp

About Persistence Market Research

Overview:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact

Rajendra Singh
Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
+1-646-568-7751
United States
USA - Canada Toll-Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Visit Our Website: https://www.persistencemarketresearch.com

Logo: https://mma.prnewswire.com/media/661339/Persistence_Market_Research_Logo.jpg

© 2021 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.